



Final Appraisal Recommendation

Advice No: 1619 – November 2019

**Cefepime dihydrochloride monohydrate (Renapime®)
1 g and 2 g powder for solution for injection or infusion**

Limited submission by Renascience Pharma Ltd

Recommendation of AWMSG

Cefepime (Renapime®) is recommended as an option for restricted use within NHS Wales.

Cefepime (Renapime®) is licensed for the treatment of infections caused by bacteria that are cefepime-sensitive: lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis; uncomplicated and complicated urinary tract infections, including pyelonephritis; skin and subcutaneous infections; intra-abdominal infections, including peritonitis and biliary tract infections; gynaecological infections; bacterial meningitis in infants and children; in combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection; treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Cefepime (Renapime®) is restricted for use for resistant pseudomonas infections where first-line agents are not effective or contraindicated.

Cefepime (Renapime®) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4129), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1619:
Cefepime dihydrochloride monohydrate (Renapime®) 1 g and 2 g powder for solution for injection or infusion. November 2019

